Key Takeaways
- Best quarter in ~5 years on all profitability metrics: Base business revenue grew 37% YoY to ₹327 crores, EBITDA rose 68% YoY with margin up ~440 bps to 23.6%, and ibuprofen narrowed to near breakeven.
- Gross margin headwinds are structural, not transient: Base business gross margin fell to ~50% from a historical 53–55% range because the company cannot fully pass on input-cost increases from the West Asia crisis, and management expects this pressure to persist for one to two more quarters.
- Ibuprofen recovery is real but fragile: Revenue grew 21% YoY and the segment reached breakeven, yet management attributes the improvement partly to factors outside its control and cannot guarantee repeatability if market conditions normalize.
- The strategic review is the main event: A 12-week review covering ibuprofen, CRAMS, and the mothballed Vizag facility will determine whether the plant is repurposed into a multi-product facility or sold; the outcome is promised within 12 weeks.
- What to watch next quarter: Whether ibuprofen can hold breakeven without the tailwind of favorable market dynamics, the pace of base business gross margin recovery, and the strategic review decision on Vizag and ibuprofen.
Base Business Performance
- Revenue momentum sustained: Base business revenue stayed above ₹300 crores for the third consecutive quarter, with regulated markets contributing ~78% of the mix, reflecting a healthy product profile.
- Volume-led growth: Of the consolidated revenue of ~₹418 crores, price increases contributed only ₹25–30 crores; the rest came from volume expansion.
- EBITDA margin resilience: Despite the gross margin drop, EBITDA margins held and improved because the cost base stayed flat at ~₹120 crores, allowing incremental gross margin from volume expansion to flow through to EBITDA, with scope for further improvement as volume expansion plays through.
- Gross margin pressure mechanism: The base business gross margin fell to ~50% from the historical 53–55% range because Solara has been unable to fully pass on input-cost increases to customers at every stage, with every customer and every product.
- Headwind duration: Management expects gross margin headwinds to persist for at least one to two more quarters based on current industry dynamics, though the possibility of improvement always exists; multi-quarter contracts are not the norm in the API environment, making precise near-term forecasting difficult.
Rao: "That depends on how long the crisis lasts, so that's beyond us. But we have learned to live with the crisis and make the most of the situation."
Ibuprofen: Recovery & Uncertainty
- Sharp QoQ improvement: Revenue grew 21% YoY and 18% QoQ to ₹91 crores, supported by better price realizations and higher volumes. The loss narrowed to near breakeven from a roughly ₹9 crore loss in Q1, and the loss margin was around 21% just two quarters ago.
- Gross margin recovery: Ibuprofen gross margin recovered to 36%, driven by changing market dynamics including a spike in demand and slightly better pricing.
- External tailwinds, not structural fix: The improvement was driven by macroeconomic conditions, the West Asia crisis (rising solvent prices, raw material issues), and customers helping by increasing prices given Solara's credibility. Management explicitly states these factors are partly outside its control and cannot guarantee repeatability.
- Competitive landscape in flux: Indian players are increasing capacity while some Western players are reportedly shutting down facilities; Solara is waiting and watching, focusing on marquee customers with sticky, long-term associations and avoiding low-margin business.
- Q3 profitability uncertain: Whether ibuprofen stays profitable in Q3 depends on macroeconomic factors, the ability to pass on costs, solvent price management, and raw material availability. If market conditions normalize, the business could return to ₹10–15 crore quarterly losses.
Rao: "There are players in India who are increasing their capacity... And then on the other side you have players in the Western world who we hear are shutting down their facilities. So this is a time where we are just waiting and watching."
Strategic Review: Ibuprofen, Vizag & CRAMS
- 12-week timeline: A strategic review is underway covering the CRAMS piece, the Vizag piece, and ibuprofen; management estimates it will close in 12 weeks and will provide an update on the outcome and next steps.
- Ibuprofen options unchanged: The two options remain (1) repurposing the plant from a single-product dedicated facility into a multi-product facility, including intermediates for captive consumption, and (2) finding an appropriate buyer.
- Vizag facility mothballed: No manufacturing is currently taking place at Vizag; certain unutilized ibuprofen equipment was sold in Q2, recording a ₹4.5 crore exceptional loss, but this is unrelated to the site as a whole. No further exceptional items are foreseen from Vizag at this point, though a wider assessment is possible after the strategic review concludes.
- CRAMS is background, not foreground: The CRAMS business is very small today; management hopes to build traction over the next few years, but the near-term focus is on existing products, debottlenecking, operational excellence, cash generation, expanding reach, and invigorating R&D.
Rao: "Nothing has changed in our options... One is repurposing the plant from being a single product dedicated facility into a multi-product facility... And of course, the other option is the eternal option of finding an appropriate buyer who can take the facility."
Balance Sheet & Cash Flows
- Net debt reduction: Net debt reduced to ~₹500 crores from ₹614 crores in March 2026, with ₹100 crores from the rights issue and ₹14 crores from operating cash flows.
- Finance cost benefit: Net finance cost dropped ~17% QoQ due to the debt reduction of ~₹114 crores in H1.
- Net debt to EBITDA ratio: Expected to remain in a similar range (~1.8x) over the next medium term.
- Trade receivables increase: Driven by two operational factors rather than payment-term extensions: (1) the revenue base is up ~50%+ YoY, and (2) quarter-end billing linearity is challenged because most billing happens in the last 7–10 days and container availability issues extend shipment SLAs from 2–3 days to 5–7 days.
- Inventory build: Inventory rose ~₹20 crores due to raw material security concerns and supply issues; the company is building sufficient stocking for manufacturing flexibility.
Regulatory & Pipeline Progress
- DMF filings restarting: Solara filed its second DMF for FY27 (one in Q1, one in Q2) and is targeting three more before FY27 end, totaling five for the year, coming from zero DMF filings in the prior three years. Management confirmed the trajectory of filing two to four DMFs per year over the next three years, after an analyst asked if they would continue that trajectory.
- Regulatory audit success: The Mangalore facility successfully completed an Anvisa audit in August 2026, following the Cuddalore facility's successful Anvisa audit in May 2026.
- ESG rating upgrade: CRISIL upgraded Solara's ESG rating from 'adequate' to 'strong'.
- Valbenazine DMF: An analyst asked about the outlook with the US customer, whether Solara is the sole supplier, and dynamics on the filing; management declined to discuss specifics on the call, offering to take the question offline.
Margin Outlook & Operating Leverage
- Sustainable gross margin target: Management is comfortable sustaining a 52–55% base business gross margin range; the Q2 reported ~50.5% would be ~53%+ adjusted for unrecovered raw material price increases from the West Asia crisis.
- Cost base discipline: The operating cost base is expected to remain flattish in the current range (±2–3%), so any gross margin expansion from volume or territory expansion should flow significantly through to EBITDA.
- Operational excellence underway: The company is working on managing opex and creating meaningful capacity through debottlenecking with incremental capex for high-margin products to improve EBITDA.
- EBITDA margin expansion path: Scope exists for EBITDA margin improvement through territory expansion and higher wallet share from existing customers; timelines range from a few months to a few quarters.
- Turnaround bar: Management would consider the business turned around only after two more quarters in line with or better than the current quarter.
Rao: "I'd be cautiously optimistic. I would say we've turned around if we can get another two quarters in line with the current quarter or better than the current quarter."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Strategic review outcome | Decision on ibuprofen plant (repurpose or sell), Vizag, and CRAMS | 12 weeks from call date |
| DMF filings | Three more DMFs in FY27, totaling five for the year | By FY27 end |
| DMF filing trajectory | Two to four DMFs per year | Next three years |
| Base business gross margin | Sustain 52–55% range (adjusted for unrecovered input costs) | Ongoing; headwinds persist 1–2 more quarters |
| Operating cost base | Remain flattish in current range (±2–3%) | Ongoing |
| Net debt to EBITDA | Remain ~1.8x | Medium term |
| Turnaround confirmation | Two more quarters in line with or better than Q2 FY27 | Two quarters |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹418 crores, up 33% YoY |
| EBITDA | ₹77 crores, up 118% YoY |
| EBITDA margin | 18.4%, up ~720 bps YoY and ~200 bps QoQ |
| PAT | ₹28.5 crores, vs loss of ~₹10 crores in Q2 FY26; highest in five years |
| EPS | ₹5.92 per share; adjusted for exceptional item would have been ~₹1 higher |
| Gross margin | 47.2%, ~200 bps lower YoY due to West Asia crisis input costs |
| Base business revenue | ₹327 crores, up 37% YoY; third consecutive quarter above ₹300 crores |
| Base business EBITDA margin | 23.6%, up ~440 bps YoY |
| Base business gross margin | 50%+, slightly lower than previous quarters due to product mix and input costs |
| Ibuprofen business revenue | ₹91 crores, up 21% YoY and 18% QoQ |
| Ibuprofen EBITDA | Near breakeven, vs ~₹9 crore loss in Q1 FY27; loss margin was ~21% two quarters ago |
| Ibuprofen gross margin | 36%, recovered driven by changing market dynamics |
| Net debt | ~₹500 crores, down from ₹614 crores as of Mar 2026 |
| Net debt to EBITDA | ~1.8x, improved from 3.2x last year |
| H1 FY27 EBITDA | ~₹140 crores, up 51% YoY; margin 17.5% vs ~15% in H1 FY26 |
| H1 FY27 PAT | ~₹45 crores, vs near breakeven in H1 FY26 |
| Regulated markets revenue share | ~78% of revenues |
| DMF filings in FY27 | 2 filed (Q1 and Q2), targeting 5 for the full year |
| Exceptional loss (Vizag equipment sale) | ₹4.5 crores, one-off monetization of unutilized ibuprofen assets |